IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Pharmaron Beijing   / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/pharmaron-beijing-co-ltd-a" target="_blank" data-smartkarma-citation="entities:28277:1" rel="noopener">Pharmaron Beijing Co., Ltd. (A) (300759 CH)</a> is a global contract research organisation (CRO) and is one of the top three drug discovery service providers globally in terms of total revenue in 2018, according to Frost &amp; Sullivan. Just seven months from its A-Share listing which raised net proceeds of $61 million, Pharmaron has filed for a Hong Kong IPO to raise around $500 million.</p><div class="content-highlight"><p>Pharmaron’s A-shares have more than quadrupled since the IPO with the market cap currently at RMB27.7 billion ($3.9 billion). Overall, we believe that Pharmaron fundamentals are solid. As investors can gain exposure to the CRO industry through several listed competitors, in our next note, we will carry out a benchmarking study to gauge Pharmaron’s relative attractiveness.</p></div>

Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers globally in terms of total revenue in 2018, according to Frost &amp; Sullivan. Just seven months from its A-Share listing which raised net proceeds of $61 million, Pharmaron has filed for a Hong Kong IPO to raise around $500 million.Pharmaron’s A-shares have more than quadrupled since the IPO with the market cap currently at RMB27.7 billion ($3.9 billion). Overall, we believe that Pharmaron fundamentals are solid. As investors can gain exposure to the CRO industry through several listed competitors, in our next note, we will carry out a benchmarking study to gauge Pharmaron’s relative attractiveness.

Pharmaron Beijing IPO Initiation: Clinically Sound

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<p>Pharmaron, a leading contract research company, is looking to list on the H-Share market by raising up to USD 600 million. In this insight, we will look at the company's background, revenue model, management and investors of the company.</p>
<p>The company has a good reputation in the CRO/CMO industry, as evidenced by its international pharmaceutical clients. We are of the view that the company's management has a strong track record and it has strong investor backing.  </p>

Pharmaron, a leading contract research company, is looking to list on the H-Share market by raising up to USD 600 million. In this insight, we will look at the company's background, revenue model, management and investors of the company.
The company has a good reputation in the CRO/CMO industry, as evidenced by its international pharmaceutical clients. We are of the view that the company's management has a strong track record and it has strong investor backing.  

Pharmaron (康龙化成) A+H Listing: A Leading Drug Discovery Company

China

Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmaron Beijing (300759 CH)

Pharmaron Beijing IPO Initiation: Clinically Sound

Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service...

Arun George

Pharmaron (康龙化成) A+H Listing: A Leading Drug Discovery Company

Pharmaron, a leading contract research company, is looking to list on the H-Share market by raising up to USD 600 million. In this insight, we will...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)